What we're reading, February 11, 2016: Plaintiffs lose their case against cigarette manufacturer; the politics behind providing care for those infected with Zika; and of course, prescription drug prices.
Longtime smokers of Marlboro cigarettes have lost their liability fight against the cigarette manufacturer Philip Morris USA. According to a report in the Chicago Tribune, a jury unanimously rejected a claim filed 10 years back that Marlboros are defective and dangerous. If they had won, the plaintiffs would have been eligible to receive screening chest scans estimated to cost $500.
Meanwhile, as the Zika virus continues its rampage in Latin America, the CDC believes Puerto Rico might be hit hard by the outbreak along with some other US territories. According to Reuters, CDC director Tom Frieden, MD, MPH, shared the information with the House Foreign Affairs subcommittee. Republican lawmakers who led the hearing, meanwhile, played abortion politics saying they hoped that infected women will not have abortions to avoid giving birth to children with developmental problems.
At another hearing on the Hill, HHS secretary Silvia Mathews Burwell was up defending the president’s budget—she told lawmakers that the administrations is delving into every option that can help control prescription drug prices. Burwell responded to Senator Jim McDermott’s (D-Washington) statement of support for Medicare to be able to negotiate prescription drug prices, saying that prescription prices are an increasing part of the Medicare budget and Veterans Administration has successfully negotiated lower prices.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More